Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Photo

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF (cellcept) in an Experimental Systemic Lupus Erythematosus Model


  • Please log in to reply
No replies to this topic

#1 janey

janey

    Platinum Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 2,118 posts
  • Location:New Mexico

Posted 24 June 2011 - 10:13 AM

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide (CYC) and MMF (cellcept) in an Experimental Systemic Lupus Erythematosus (SLE) Model.

Vidofludimus was as effective as CYC and MMF in inhibiting progression parameters of renal disease. Furthermore, vidofludimus improved activity and chronicity indices, markers of renal inflammation. Business Wire. 05/27/11. (Also see: Lupus)

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
Janey Willis
ISN Support Specialist
(Retired) ISN Assistant Webmaster
(Retired) ISN News Director
(Retired) ISN Technical Writer for Training Manuals
International Scleroderma Network (ISN)